CVE:HEMHemostemix Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Hemostemix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day RangeC$0.01MA: C$0.01▼C$0.0252-Week Range N/AVolume216,000 shsAverage Volume1.22 million shsMarket CapitalizationC$9.07 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlinesSocial Media Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Hemostemix. Previous Next 2.7 Community Rank Outperform VotesHemostemix has received 62 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHemostemix has received 51 “underperform” votes. (Add your “underperform” vote.)Community SentimentHemostemix has received 54.87% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Hemostemix and other stocks. Vote “Outperform” if you believe HEM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HEM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHemostemix does not currently pay a dividend.Dividend GrowthHemostemix does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hemostemix insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Hemostemix are expected to grow in the coming year, from C($0.01) to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hemostemix is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hemostemix is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.67 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:HEM Previous Symbol CUSIPN/A CIKN/A Webwww.hemostemix.com Phone+1-403-3409207Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow10.00 Book ValueC($0.01) per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares730,162,000Market CapC$9.07 million Next Earnings DateN/A OptionableNot Optionable TSXV:HEM Rates by TradingView Receive HEM News and Ratings via Email Sign-up to receive the latest news and ratings for HEM and its competitors with MarketBeat's FREE daily newsletter. Hemostemix (CVE:HEM) Frequently Asked Questions Has Hemostemix been receiving favorable news coverage? News articles about HEM stock have trended somewhat negative on Wednesday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Hemostemix earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Hemostemix. Who are some of Hemostemix's key competitors? Some companies that are related to Hemostemix include Hvivo (HVO), Microbix Biosystems (MBX), Ixico (IXI), Emerald Health Therapeutics (EMH), ContraVir Pharmaceuticals (HEPA), Proteomics Int Lab (PIQ), Pharmaust (PAA), Actinium Pharmaceuticals (ATNM), IntelGenx Technologies (IGX), Redx Pharma (REDX), Kazia Therapeutics (KZA), NovaBay Pharmaceuticals (NBY), Noxopharm (NOX), Prana Biotechnology (PBT) and Armata Pharmaceuticals (ARMP). View all competitors. What other stocks do shareholders of Hemostemix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hemostemix investors own include Iplayco (IPC), Capricor Therapeutics (CAPR), General Electric (GE), Gene Biotherapeutics (CRXM), Camber Energy (CEI), Auxly Cannabis Group (CBWTF), Cannabis Science (CBIS), Beazer Homes USA (BZH), Big Tree Group (BIGG) and Asterias Biotherapeutics (AST). Who are Hemostemix's key executives? Hemostemix's management team includes the following people: Mr. Kyle Makofka, Chief Exec. OfficerMs. Kristin Gulka CPA, CA, Chief Financial OfficerMs. Eilat Bain, Director of OperationsDr. Alan J. Jacobs, Chief Medical Consultant What is Hemostemix's stock symbol? Hemostemix trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HEM." How do I buy shares of Hemostemix? Shares of HEM and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. How big of a company is Hemostemix? Hemostemix has a market capitalization of C$0.00. What is Hemostemix's official website? The official website for Hemostemix is www.hemostemix.com. How can I contact Hemostemix? Hemostemix's mailing address is Bay 1, PO Box 10, BLACKFALDS, AB T0M 0J0, Canada. The biotechnology company can be reached via phone at +1-403-3409207. This page was last updated on 7/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
